ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Ceridian HCM Holding Inc

Ceridian HCM Holding Inc (DAY)

94.31
0.00
(0.00%)
Closed February 06 3:12PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
94.31
Bid
91.78
Ask
105.10
Volume
-
0.00 Day's Range 0.00
64.24 52 Week Range 115.53
Market Cap
Previous Close
94.31
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
20,267
Shares Outstanding
156,127,000
Dividend Yield
-
PE Ratio
198.06
Earnings Per Share (EPS)
0.35
Revenue
1.51B
Net Profit
54.8M

About Ceridian HCM Holding Inc

Sector
Prepackaged Software
Industry
Prepackaged Software
Headquarters
Wilmington, Delaware, USA
Founded
-
Ceridian HCM Holding Inc is listed in the Prepackaged Software sector of the Toronto Stock Exchange with ticker DAY. The last closing price for Ceridian HCM was $94.31. Over the last year, Ceridian HCM shares have traded in a share price range of $ 64.24 to $ 115.53.

Ceridian HCM currently has 156,127,000 shares outstanding. The market capitalization of Ceridian HCM is $14.72 billion. Ceridian HCM has a price to earnings ratio (PE ratio) of 198.06.

DAY Latest News

Dayforce Reports Fourth Quarter and Full Year 2024 Results1

Dayforce® recurring revenue of $347.9 million, up 19% year-over-year in the fourth quarter Total revenue of $465.2 million, up 16% year-over-year in the fourth quarter Full year 2024 net cash...

Dayforce to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 5th

MINNEAPOLIS and TORONTO, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Dayforce, Inc. (NYSE:DAY) (TSX:DAY), a global human capital management (HCM) leader that makes work life better, today announced that...

Dayforce Wallet Surpasses $5 Billion Milestone

MINNEAPOLIS and TORONTO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Dayforce, Inc. (NYSE: DAY; TSX: DAY), a global human capital management (HCM) leader that makes work life better, today announced two...

Dayforce Introduces Dayforce Communications

MINNEAPOLIS and TORONTO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Dayforce, Inc. (NYSE: DAY; TSX: DAY), a global human capital management (HCM) leader that makes work life better, today introduced...

15th Annual Dayforce Pulse of Talent Report: Leaders Face Balancing Act Between Culture and the Need for Efficiency and Agility

MINNEAPOLIS and TORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Dayforce, Inc. (NYSE: DAY; TSX: DAY), a global human capital management (HCM) leader that makes work life better, today released...

Dayforce Elevates Partner Experience with Enhanced Dayforce Partner Network

MINNEAPOLIS and TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Dayforce, Inc. (NYSE: DAY; TSX: DAY), a global human capital management (HCM) leader that makes work life better, today announced key...

Dayforce Reports Third Quarter 2024 Results¹

Dayforce® recurring revenue of $333.2 million, up 19% Total revenue of $440.0 million, up 17% Year-to-date net cash provided by operating activities of $200.1 million, up 54% MINNEAPOLIS and...

Dayforce Named a Leader in the 2024 Gartner® Magic Quadrant™ for Cloud HCM Suites for 1,000+ Employee Enterprises for Fifth Consecutive Year

MINNEAPOLIS and TORONTO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Dayforce, Inc. (NYSE: DAY; TSX: DAY), a global human capital management (HCM) leader that makes work life better, today announced it...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-9.09-8.79110251451103.4103.990.362216098.5125194CS
4-7.04-6.94622594968101.35107.8390.3615235100.77052855CS
12-13.24-12.3105532311107.55115.5390.3620267106.88945137CS
2621.3929.333516182172.92115.5369.8818664100.14164028CS
520.210.22316684378394.1115.5364.241615091.12413044CS
1561.11.1801308872493.21115.5364.241607291.15246609CS
2601.11.1801308872493.21115.5364.241607291.15246609CS

DAY - Frequently Asked Questions (FAQ)

What is the current Ceridian HCM share price?
The current share price of Ceridian HCM is $ 94.31
How many Ceridian HCM shares are in issue?
Ceridian HCM has 156,127,000 shares in issue
What is the market cap of Ceridian HCM?
The market capitalisation of Ceridian HCM is CAD 14.72B
What is the 1 year trading range for Ceridian HCM share price?
Ceridian HCM has traded in the range of $ 64.24 to $ 115.53 during the past year
What is the PE ratio of Ceridian HCM?
The price to earnings ratio of Ceridian HCM is 198.06
What is the cash to sales ratio of Ceridian HCM?
The cash to sales ratio of Ceridian HCM is 7.17
What is the reporting currency for Ceridian HCM?
Ceridian HCM reports financial results in USD
What is the latest annual turnover for Ceridian HCM?
The latest annual turnover of Ceridian HCM is USD 1.51B
What is the latest annual profit for Ceridian HCM?
The latest annual profit of Ceridian HCM is USD 54.8M
What is the registered address of Ceridian HCM?
The registered address for Ceridian HCM is 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808
What is the Ceridian HCM website address?
The website address for Ceridian HCM is www.dayforce.com
Which industry sector does Ceridian HCM operate in?
Ceridian HCM operates in the PREPACKAGED SOFTWARE sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
134AUPraise Inc
 0.00
(0.00%)
0
1332Nissui Corporation
 0.00
(0.00%)
0
132AIN Holdings Co Ltd
 0.00
(0.00%)
0
131ACCN Group Corp
 0.00
(0.00%)
0
130AVeritas In Silico Inc
 0.00
(0.00%)
0
134AUPraise Inc
 0.00
(0.00%)
0
1332Nissui Corporation
 0.00
(0.00%)
0
132AIN Holdings Co Ltd
 0.00
(0.00%)
0
131ACCN Group Corp
 0.00
(0.00%)
0
130AVeritas In Silico Inc
 0.00
(0.00%)
0
134AUPraise Inc
 0.00
(0.00%)
0
1332Nissui Corporation
 0.00
(0.00%)
0
132AIN Holdings Co Ltd
 0.00
(0.00%)
0
131ACCN Group Corp
 0.00
(0.00%)
0
130AVeritas In Silico Inc
 0.00
(0.00%)
0

Discussion

View Full Feed
JSmith5 JSmith5 5 minutes ago
HUD's Turner only puts the word Congress in his mouth to facilitate Pulte's confirmation. The release process will be done administratively.

Completely agree - And I am sure that Pulte say that he will "consult with congress" about 50 times during his hearing.

Nats
FNMA
Mark Mark 5 minutes ago
$EQ .99 on watch
EQ
glenn1919 glenn1919 5 minutes ago
EQ.....................MULN....................................https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=3&dy=0&id=p11960084343
MULN
oystersnbeer oystersnbeer 6 minutes ago
By Maga standards ,
You’re a Genius!
BlazingStocks BlazingStocks 6 minutes ago
$BURU - Nuburu’s AO Series are covered by one or more of the following Untied States and foreign patents and patent applications
https://www.nuburu.net/patents/
BURU
glenn1919 glenn1919 6 minutes ago
EQ................................https://stockcharts.com/h-sc/ui?s=EQ&p=W&b=5&g=0&id=p86431144783
EQ
georgie18 georgie18 6 minutes ago
ALLR...$1.23...🥳... https://www.globenewswire.com/news-release/2025/02/06/3021970/0/en/Allarity-Therapeutics-Announces-Expansion-of-Phase-2-Clinical-Trial-to-Accelerate-Development-of-Stenoparib-in-Advanced-Ovarian-Cancer.html
ALLR
mike_dotcom mike_dotcom 7 minutes ago
Another week of nothing except a declining stock price.
AVXL
georgie18 georgie18 7 minutes ago
ALLR...$1.23...🥳... https://www.globenewswire.com/news-release/2025/02/06/3021970/0/en/Allarity-Therapeutics-Announces-Expansion-of-Phase-2-Clinical-Trial-to-Accelerate-Development-of-Stenoparib-in-Advanced-Ovarian-Cancer.html
ALLR
chereb19 chereb19 7 minutes ago
The primary objective of this phase I trial is to assess the safety and feasibility of the treatment.
Notably, one patient experienced an exceptional 80% reduction in tumor size during this trial so far. Such a significant response is uncommon in phase I trials, which are primarily designed t
RDGL
georgie18 georgie18 7 minutes ago
ALLR...$1.23...🥳... https://www.globenewswire.com/news-release/2025/02/06/3021970/0/en/Allarity-Therapeutics-Announces-Expansion-of-Phase-2-Clinical-Trial-to-Accelerate-Development-of-Stenoparib-in-Advanced-Ovarian-Cancer.html
ALLR
TheDane TheDane 7 minutes ago
SMCI announced a business update for Feb. 11. They released news about “ramping up” at one the AI data center. These two items are positive for the company and shareholders so why wouldn’t that be the more obvious reason for the rise in share price? Especially since it dropped significantly the week
SMCI
Here Today Here Today 7 minutes ago
News is Out!!!!!
RNAZ
georgie18 georgie18 7 minutes ago
ALLR...$1.23...🥳... https://www.globenewswire.com/news-release/2025/02/06/3021970/0/en/Allarity-Therapeutics-Announces-Expansion-of-Phase-2-Clinical-Trial-to-Accelerate-Development-of-Stenoparib-in-Advanced-Ovarian-Cancer.html
ALLR
subslover subslover 8 minutes ago
😁CONGRATS!😷
LIPO
chereb19 chereb19 8 minutes ago
Fantasy products made up by you don't really exist.

Why don't you site the clinical trials here

https://trialsearch.who.int/

If you can't , they don't exist
RDGL
royal1 royal1 8 minutes ago
I made my money following the bashers and i am sure that i am not the only one.
HMBL
Mark Mark 8 minutes ago
$RLMD .46
RLMD
Mark Mark 8 minutes ago
$RLMD .46
RLMD
Dallas-Cowboys Dallas-Cowboys 9 minutes ago
Huh you find that strange that he is dealing with the deaths of 74 people and a Learjet accident where the cause could effect every Learjet out there. I find your post strange
TGLO
Magnum7419 Magnum7419 9 minutes ago
how does one have zero followers /?
AHRO
sharkey1 sharkey1 9 minutes ago
Its always the day after they release financials after hours.
ELTP
Trooperstocks Trooperstocks 10 minutes ago
NEWS: $ZENA ZenaTech’s ZenaDrone Starts Testing its High-Density Batteries to Extend Flight Time for ZenaDrone 1000 Drone for US Defense Applications

February 06, 2025 07:30 ET | Source: ZenaTech Inc.

VANCOUVER, British Columbia, Feb. 06, 2025 (GLOBE NEWSWIRE) -- ZenaT
ZENA
georgie18 georgie18 11 minutes ago
IMRX...$1.99...🥳... https://www.globenewswire.com/news-release/2025/02/06/3021891/0/en/Immuneering-Announces-Clinical-Supply-Agreement-with-Regeneron-Pharmaceuticals-to-Evaluate-IMM-1-104-in-Combination-with-Libtayo-cemiplimab.html
IMRX
Trooperstocks Trooperstocks 11 minutes ago
$ZENA $4.89 +4.94% on pre-market news!
ZENA

Your Recent History

Delayed Upgrade Clock